Protection of study subjects
Executive SummaryFDA issues a draft guidance specifying the responsibilities investigators have to protect the rights and safety of patients participating in clinical trials. FDA says the agency became increasingly aware that current guidance and regulation - codified primarily in the 1970s - did not adequately address the increasing complexity of the modern clinical enterprise, including outsourcing. Comments are due by July 9...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.